Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors thank the patients and their families. The authors acknowledge the support of Elizabeth Weber, BSN, RN, in her coordination of these patients.

Author contributions

WA drafted the manuscript. GK designed research, managed the patients, and drafted the manuscript. NY-R drafted the manuscript. JPP edited the manuscript. SJS managed patients and edited the manuscript. EAC conceived of research, designed research, managed the patients, and drafted the manuscript.

Disclosure statement

EAC reports advisory boards for Beigene and AstraZeneca; and research funding from Genentech/Roche and AbbVie. SJS reports advisory boards participation Abbvie, AstraZeneca, BeiGene, CariBou Biotech, Genentech/Roche, Genmab, Incyte/Morphosys, Kite Pharma, Legend Biotech, Novartis, Mustang Biotech, Nordic Nanovector; honoraria for Incyte/Morphosys, Takeda; steering committee participation for CariBou Biotech, Genentech/Roche, Genmab, Legend Biotch, Novartis, Nordic Nanovector; DSMB for Fate Therapeutics; and Research Support from Genentech/Roche, Genmab. The remaining authors have no conflicts.

Additional information

Funding

EAC is supported by a Lymphoma Research Foundation Clinical Investigator Career Development Award.